Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)
All News about Viridian Therapeutics, Inc. - Common Stock



Via Benzinga



11 Analysts Have This to Say About Viridian Therapeutics
June 14, 2023
Via Benzinga

Analyst Ratings for Viridian Therapeutics
May 10, 2023
Via Benzinga

Recap: Viridian Therapeutics Q1 Earnings
May 09, 2023
Via Benzinga




Earnings Outlook For Viridian Therapeutics
May 08, 2023
Via Benzinga

Expert Ratings for Viridian Therapeutics
April 17, 2023
Via Benzinga

Analyst Expectations for Viridian Therapeutics's Future
March 30, 2023
Via Benzinga

Via Benzinga


Via Benzinga

Analyst Expectations for Viridian Therapeutics's Future
March 09, 2023
Via Benzinga



Via Benzinga

Viridian Therapeutics Earnings Preview
March 07, 2023
Via Benzinga

The Latest Analyst Ratings for Viridian Therapeutics
February 07, 2023
Via Benzinga

Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
December 23, 2022
Via Benzinga


Via Benzinga

Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
December 19, 2022
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free